Does anyone know Aspen Pharmaceuticals? What is the job outlook for medical representatives at this company?

When mentioning Aspen, many people still look puzzled—but colleagues working in anesthesia and thrombosis products are likely already familiar with this low-profile, largest pharmaceutical company in South Africa. Aspen Pharmacare (Aspen) was founded in 1997, headquartered in South Africa. Since its inception, its core business has centered on generic drugs, growing into one of the world’s top 50 pharmaceutical companies—a truly impressive achievement, often dubbed the ‘South African Mylan.’ In June 2016, Aspen acquired AstraZeneca’s global anesthesia business, including seven products such as Diprivan and Emla. In September of the same year, Aspen acquired GlaxoSmithKline’s thrombosis and anesthesia portfolio, comprising anticoagulants (e.g., Fraxiparine, Fragmin) and anesthetics (e.g., Nimbex, Mivacron, Curare, Scoline). In March 2017, Aspen held its first annual China regional meeting in Sanya—marking the official establishment of Aspen China!

Top 10 Global Generic Drug Companies in 2021! Breaking Through Pandemic-Driven Obstacles—Opportunities for Growth in the Generic Drug Sector Are Maturing.

Headquarters: Hyderabad, India 2021 Generic Drug Sales: USD 3.18 billion 2020 Generic Drug Sales: USD 2.97 billion Change: +7% Aurobindo’s 2021 sales totaled INR 247.7 billion (approximately USD 3.18 billion), representing a 7% increase over 2020. The majority of Aurobindo’s 2021 revenue came from its formulations business, accounting for 88% of total revenue; the remaining 12% came from its active pharmaceutical ingredients (API) division, which operates 11 manufacturing facilities across India. As of March 31, 2021, the company held a 6.8% market share of U.S. prescription formulations. Most of Aurobindo’s U.S. revenue derived from oral and injectable drugs, representing 66.9% and 15%, respectively, of its U.S. formulations revenue. Meanwhile, the company is actively seeking to broaden its product portfolio—including oncology drugs, inhalers, biosimilars, topicals, and transdermal patches. The European market contributed one-quarter of Aurobindo’s total revenue. Additionally, the company has begun filing regulatory submissions for products manufactured at its Chinese facilities and recently secured its first market approval in China for a drug produced at one of its Indian plants. For 2022, however, Aurobindo faces significant challenges. In June of this year, generic competitor Teva successfully blocked Aurobindo’s recently launched potential generic version of Austedo—a drug used to treat tardive dyskinesia—which generated USD 820.2 million in revenue in 2021. The company also had to contend with an FDA warning letter, an antibiotic recall, plant shutdowns, and separate FDA manufacturing reports—all occurring within roughly five months. 7. Cipla Headquarters: Mumbai, India 2021 Generic Drug Sales: USD 2.65 billion 2020 Generic Drug Sales: USD 2.47 billion Change: +7.3% The company’s global sales last year totaled USD 2.65 billion, up 7.3% from USD 2.47 billion in 2020. Financial filings indicate that growth was driven by strong performance in U.S., Indian, and other international equity markets. In India, the company achieved double-digit revenue growth, partly fueled by its COVID-19 treatment portfolio. In South Africa, Cipla repeatedly reported ‘market-beating growth’ in its annual financial statements. During the pandemic, Cipla partnered with Pfizer to manufacture the antiviral drug Paxlovid for 95 low- and middle-income countries. Earlier, in May 2020, Cipla entered a licensing agreement with Gilead Sciences to market and sell remdesivir under its own brand name across 127 countries—including India and South Africa. Meanwhile, in the U.S., numerous companies—including Cipla—rushed to launch generic versions of Bristol Myers Squibb’s blockbuster multiple sclerosis drug Revlimid. Like others, Cipla holds rights to begin selling its generic version after a confidential date following March 2022. However, launching the generic still requires formal FDA approval.

South Africa's Aspen Pharmacare to Sell Women's Health Product in Europe to Ennogen

16 hours ago

South Africa's Aspen Pharmacare sold European commercialization rights for its women's health product Ovestin to Ennogen Healthcare International for €197 million. Under the deal, Aspen will maintain long-term supply of the active ingredient and formulation for at least 10 years.

reuters

2026-11-02

South Africa's Aspen Pharmacare to Sell Women's Health Product in Europe to Ennogen

South Africa's Aspen Pharmacare to Sell Women's Health Product in Europe to Ennogen

FAQ